APHA:CA:TSX-Aphria Inc (CAD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | TSX

Last Closing Price

CAD 16.55

Change

0.00 (0.00)%

Market Cap

CAD 4.44B

Volume

9.61M

Avg Analyst Target

N/A

Avg User Target

CAD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Aphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands. It serves patients and consumers through distributors and online. The company is headquartered in Leamington, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-23 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BHC:CA Bausch Health Companies Inc

N/A

CAD12.74B N/A 25.81
WEED:CA Canopy Growth Corporation

N/A

CAD6.50B N/A N/A
TLRY:CA Tilray Inc

N/A

CAD6.36B N/A N/A
CRON:CA Cronos Group Inc

N/A

CAD2.59B 46.76 N/A
ACB:CA Aurora Cannabis Inc

N/A

CAD1.73B 1,171.00 N/A
OGI:CA OrganiGram Holdings Inc

N/A

CAD0.86B -99,999.99 N/A
HLS:CA HLS Therapeutics Inc

N/A

CAD0.64B N/A 31.16
GUD:CA Knight Therapeutics Inc

N/A

CAD0.64B 11.44 5.35
HEXO:CA HEXO Corp

N/A

CAD0.58B N/A N/A
TH:CA Theratechnologies Inc

N/A

CAD0.41B 954.70 80.88

ETFs Containing APHA:CA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 88.07% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 88.07% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 177.22% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 177.22% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 53.35% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 53.35% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 131.16% N/A N/A N/A N/A
Risk Adjusted Return 40.67% N/A N/A N/A N/A
Market Capitalization 4.44B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 57.08 N/A N/A N/A N/A
Price/Book Ratio 5.59 N/A N/A N/A N/A
Price / Cash Flow Ratio -33.19 N/A N/A N/A N/A
EV/EBITDA 598.01 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -34.14% N/A N/A N/A N/A
Return on Invested Capital -0.06% N/A N/A N/A N/A
Return on Assets -1.31% N/A N/A N/A N/A
Debt to Equity Ratio 22.09% N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.52 N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 2.62 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.